All of us have a relative or know someone who has been diagnosed with cancer. The disease brings significant uncertainty, including difficult treatment decisions. Chemotherapy is often a key option and can be highly effective, but for ovarian cancer patients with recurrent disease, the likelihood of benefit can drop below 30%.
With ChemoPredict, VitroScan provides accurate and reliable ex vivo tumor testing to support these challenging decisions. Fresh tumor tissue is collected in the hospital and sent to our centralized laboratory in Leiden. Within two weeks, we deliver a report to the doctor predicting the efficacy of the available chemotherapy. This enables better-informed treatment decisions to:
• Reduce overtreatment of ovarian cancer patients identified as resistant to specific treatments.
• Facilitate shared and personalized decision-making between doctors and patients.
• Potentially benefit all cancer patients.
With the support of Biotech Booster, VitroScan will prepare the service for quality certification in line with clinical standards. Additionally, we will conduct a prospective clinical trial to demonstrate the value of this technology for ovarian, cervical, and endometrial cancer patients. Furthermore, we will collaborate with EU hospitals and clinical experts to prepare for European-scale implementation.
In conclusion, with Biotech Booster’s support, ChemoPredict will provide predictive testing services that make a meaningful impact on doctors, patients, and the healthcare system.
